West Pharmaceutical (WST) SVP awarded restricted stock units and options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Poussot Rodolphe Jean reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services senior vice president of Strategy & Corporate Development Rodolphe Jean Poussot received equity awards on March 1, 2026. He was granted 437 restricted stock units, each representing one share of common stock, and stock options for 1,040 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Poussot Rodolphe Jean

Role SVP, Strategy & Corporate Dev

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	437	$0.00	--
Grant/Award	Stock Option (Right to Buy)	1,040	$0.00	--

Holdings After Transaction: Rst. Stock Unit — 437 shares (Direct); Stock Option (Right to Buy) — 1,040 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of WST common stock. The restricted stock units vest in four equal annual installments beginning on March 1, 2027. The stock option vests in four equal annual installments beginning on March 1, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 11:24 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poussot Rodolphe Jean

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

19341

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Strategy & Corporate Dev

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Rst. Stock Unit	⁽¹⁾	03/01/2026		A		437		⁽²⁾	⁽²⁾	Common Stock	437	$0	437	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		1,040		⁽³⁾	03/01/2036	Common Stock	1,040	$0	1,040	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Rodolphe J. Poussot	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did WST executive Rodolphe Jean Poussot receive?

He received 437 restricted stock units and stock options for 1,040 shares. Both awards were granted as derivative securities and represent additional compensation tied to West Pharmaceutical Services common stock, subject to future vesting conditions.

When do the restricted stock units granted to WST executive vest?

The 437 restricted stock units vest in four equal annual installments beginning March 1, 2027. This means one-quarter of the units convert into common shares each year over four years, if applicable service or other conditions are met.

How do the stock options granted to the WST executive vest?

The stock options covering 1,040 shares vest in four equal annual installments starting March 1, 2027. Each year, one-quarter of the options become exercisable, aligning the executive’s potential ownership with longer-term company performance and retention.

Is the Form 4 transaction for WST an acquisition or a sale?

The Form 4 reports acquisitions of derivative securities through grants, not open-market buying or selling. Both transactions are coded as awards (code A) and increase the executive’s potential future ownership in West Pharmaceutical Services common stock upon vesting or exercise.

Does the WST executive directly hold the reported equity awards?

Yes. The filing identifies the ownership of both the restricted stock units and stock options as direct. There is no footnote indicating that another entity, such as a trust or LLC, holds voting or investment authority over these awards.